AI assistant
Novartis AG — Director's Dealing 2020
Jun 10, 2020
940_dirs_2020-06-09_026e6b46-2980-4b84-9bcc-6d77fc3e7870.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Galera Therapeutics, Inc. (GRTX)
CIK: 0001563577
Period of Report: 2020-06-05
Reporting Person: Novartis Bioventures Ltd (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-06-05 | Common Stock | S | 8652 | $9.66 | Disposed | 3519450 | Direct |
| 2020-06-08 | Common Stock | S | 5659 | $9.66 | Disposed | 3513791 | Direct |
| 2020-06-09 | Common Stock | S | 7000 | $9.38 | Disposed | 3506791 | Direct |
Footnotes
F1: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.35 to $9.89. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2: Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
F3: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.50 to $9.83. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.30 to $9.56. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.